Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 okt 2013 - 07:42
Statutaire naam
Galapagos NV
Titel
Galapagos presents superior potentiator series for CF
Bericht
- Novel proprietary series to start clinical trials end of 2014
- Superior CFTR channel opening shown in cells from CF patients
- Favorable ADME/PK profile and selectivity
Mechelen, Belgium; 17 October 2013 - Galapagos NV (Euronext: GLPG) has developed a series of novel potentiators in its cystic fibrosis program. The data will be presented at the North American Cystic Fibrosis Conference taking place from 17 - 19 October in Salt Lake City, Utah.
Datum laatste update: 14 maart 2026